# Executive Summary

GyroGear is ready to launch the GyroGlove with confirmed demand from three major sales channels. We are requesting shareholder support for 6 months operating expenses to fulfill initial orders and achieve breakeven.

## Current Market Position

The team is seeing direct interest from our three major sales engines:

1. **US Veterans Association**
   1. 30 units strongly requested by 3 initial sales reps for mid-Sep delivery.
   2. Second wave of units required by mid-Oct to support newly onboarded reps and funding for the new fiscal year for VA.
2. **Distribution**
   1. **China**
      1. 10 golden samples requested immediately
      2. Next PO of 100 units, and 2000 unit Y1 expectation, conveyed in writing from distributor to Foxconn.
   2. **Japan**
      1. Initial demo set order from Japanese dealer to be placed in early Sept.
3. **Online sales**
   1. 8 orders placed (est. Dec delivery).
   2. Very minimal marketing, no paid ads.
   3. Numbers expected to scale with a marketing budget.

# Key Milestones Achieved

Please see [URL] for commercial progress to date.

* US VP Sales assessment of mid-Sep VA sales requirement - [URL].

## Milestones

* **Serial production** underway.
  + Foxconn relocated the entire production line to Shenzhen from mid-China to support scale-up and rapid shipping.
* **US sales team** built
  + 1 VP + 4 1099 sales agents signed (60+ 1099, 30+ VP candidates interviewed).
  + Target: 9 US-based sales reps in place by mid-September (NY, Texas, NoCal, SoCal, Florida).
* **US Veterans Association** sales entry completed
  + Registered on all government sales platforms via [Lovell Government Services](https://www.lovellgov.com/) in 1.5 months (typically 12-18 months if done independently)
* **CN distributor** secured (<6 mo) for Beijing and Shanghai regions.
  + South China - in discussion with several candidates including Guangzhou Pharma[[1]](#footnote-0) (LOI signed).
* **28 partnership LOIs** signed
  + Every major centre in the US, UK now knows the product. Most would like a demo unit.
  + Directors/department heads of Cleveland, Mayo, Oxford, Harvard, etc individually approached GG to sign LOIs, given their assessment of product performance on users. A few directors have unilaterally asked to consult for GG as advisors.
* **Major global medical centers** (Cleveland, Mayo, Oxford, Harvard, UCL, Peking Uni etc) expressing strong interest, requesting demo units.

GyroGear is now at a pivotal launch stage with confirmed immediate revenue opportunities and secured production capability.

While these revenues will begin to flow progressively from September 2025, we require short‑term funding to sustain operations until we achieve cash‑flow positivity.

## Financial Overview

Immediate Revenue Opportunity

* Batch 1 – 300 units: US $1.26M potential revenue (worst‑case sale period: 9 months)

Current Financial Position

* Monthly OPEX: US $84,000
* Inventory Loan: US $360,000 secured (Ong Family)

Funding Gap

* Target SAFE raise: US $500,000
* Commitments to date: US $140,000 under SAFE has been subscribed in principle, with documents issued but pending signature.

## Use of Funds

Proceeds from this SAFE round will be used to:

1. Fully fund 6 months of OPEX (US$504,000) while revenue is being recognised
2. Ensure uninterrupted operations through the launch period
3. Fulfil confirmed initial orders and maintain production momentum

## SAFE Note Funding Terms

| **Term** | **Detail** |
| --- | --- |
| Amount | US$500,000 |
| Valuation Cap | US $25,000,000 |
| Discount | 20% on next qualified financing round |
| Conversion | The SAFE will automatically convert into equity upon the next qualified equity financing round or a liquidity event. If neither occurs within 24 months from the execution date, the SAFE will convert at that time based on the valuation cap and discount terms. |

## Key Milestones & Timeline

* Shareholder response by: 30 August 2025
* Funding close target: ???
* First shipments begin: 3rd week of September 2025

## Management Commitment

The founding team and Ong Family have invested US $1.2M of personal funds over the past 9 months to bring GyroGear to this launch‑ready stage. Repayment of the Ong Family’s loan will commence only after sales of 2,000 units and operational cash‑flow is positive.

The GyroGear team is doing all possible to ensure that we sell Batch 1 as quickly as possible, using proceeds to fund the subsequent batch. Revenue from Batch 1 alone should allow GyroGear to be cashflow positive.

Following shareholder feedback over the years, we have **significantly reduced capital requirements**, lowering the need for future fundraising.

GyroGear is making maximal effort to not raise further funds. However, this is dependent on customer response and market feedback going forward.

**Call to Action**

We invite all shareholders to confirm their participation in the SAFE note by 18 August 2025, ensuring we can seize the immediate revenue opportunity and maintain uninterrupted operations to self‑sufficiency.

# 

# 

# 

# 

# Appendix

## Production Status

* Strong progress achieved to date.
* Extensive under-the-hood verification completed with critical suppliers over the past year.
* No major technical or operational issues identified.
* Critical components (internal mechanism, motors) already delivered to GyroGear as part of forward planning. Assembly underway.
* Complex components (CNC, injection moulding) underway/almost completed, ~2 weeks from first payment (maximal acceleration by Foxconn). No major issues.
* First 30 units ETA to VA Distributor by 3rd week of September.
* Completion of remaining 300 units by end September.

## OKRs

### Immediate Targets (Fulfilment in Progress)

1. 10 units – Direct-to-Consumer (D2C)
2. 10 units – China Distributor 1 (Golden Samples)
3. 30 units – US Veterans Association (3rd Week-Sep delivery)

### Short-Term Targets

1. Secure and fulfill purchase order: 100 units – China Distributor 1
2. Sell remaining units: 150 units – US VA and online sales

1. ‘Third-largest pharmaceutical wholesaler in China measured by revenues’ [↑](#footnote-ref-0)